This program is preliminary and subject to change.
| SUNDAY JUNE 3 | ||
|
0800-1100 |
||
|
1300-1600 |
||
|
1600-1700 |
Committee and Special Interest Group Meetings
|
|
|
1830-1930 |
Opening Keynote: Using Implementation Science to Improve Laboratory Stewardship |
|
|
1930-2200 |
||
| MONDAY JUNE 4 | ||
|
0730-0830 |
Clinical Biochemistry Editorial Board Meeting |
|
|
0845-0900 |
Opening Remarks |
|
|
0900-1200 |
||
|
1200-1900 |
Exhibit and Poster Viewing
|
|
|
1400-1500 |
Industry Workshops |
|
|
1400-1500 |
Show Me the Data: Enable the Transition from Volume to Value Using Your Electronic Health Record |
|
|
1400-1500 |
||
|
1400-1500 |
||
|
1600-1700 |
||
|
1600-1700 |
||
|
1600-1700 |
||
|
1700-1900 |
||
| TUESDAY JUNE 5 | ||
|
0730-0830 |
Management of Dysglycemia in Critically Ill Patients – Importance of Glucose Meter Accuracy |
|
|
0730-0830 |
||
|
0900-1200 |
Symposium: Hot Topics in Toxicology: The Opioid Crisis and Cannabis Legalization |
|
|
1200-1330 |
Lunch and Exhibit Viewing |
|
|
1300-1330 |
CSCC Council/Sponsor |
|
|
1330-1630 |
||
|
1630-1730 |
CSCC Annual General Meeting CSCC “Town Hall” |
|
|
1730-1815 |
CACB Annual General Meeting |
|
|
1830-1930 |
||
|
1930-2230 |
||
| WEDNESDAY JUNE 6 | ||
|
0730-0830 |
Breakfast Roundtables |
|
|
0900-1200 |
||
|
1200-1300 |
Annual Meetings Committee |
|
|
1230-1300 |
CDN Lab Informatics |
|
|
1300-1400 |
Committee and Special Interest Group Meetings
|
|
|
1400-1500 |
Committee and Special Interest Group Meetings
|
|
|
1400-1600 |
Committee and Special Interest Group Meetings
|
|
|
1500-1600 |
CSCC 2018 Committee |
|
|
1600-1700 |
CSCC 2018-2019 Council Meeting CACB 2018-2019 Board of Directors Meeting |
|
Opening Keynote: Using Implementation Science to Improve Laboratory Stewardship
Sunday June 3, 1830-1930
Dr. Jeremy Grimshaw, Ottawa Hospital Research Institute and the University of Ottawa
General Objectives:
At the conclusion of this session, participants will be able to:
- Define implementation science.
- Discuss how implementation science can inform laboratory stewardship efforts.
- Consider how laboratory stewardship programs can advance implementation science.
Laboratories globally are increasingly charged to undertake stewardship activities to improve appropriate laboratory testing.
Implementation science studies the determinants, processes and outcomes of improvement programs. My presentation will introduce
the audience to key concepts from implementation science and how they may help the design and delivery of laboratory stewardship
activities. I will also discuss opportunities for further collaboration between implementation scientists and laboratory specialists to further
advance knowledge about how to further optimize stewardship activities.
Symposium: The Non-Traditional Healthcare Environment
Monday June 4, 0900-1200
General Objectives:
The general objectives for the symposium are:
- Describe the challenges of delivering healthcare in non-traditional environments.
- Identify barriers to delivering healthcare in these environments.
- Discuss the priorities considered for laboratory testing performed for or in non-traditional healthcare environments.
0900-0945
Break from Protocol – a Northern Physician’s Perspective
Dr. Treena Greene, Regional Aboriginal Cancer Lead, CCO, TOH, Manotick Medical Centre and QGH
General Objectives:
At the end of this session participants will be able to:
- Discuss the indigenous perspective of care.
- Summarize an approach to culturally safe care.
- Express alternate ways to deliver care.
The presentation will elicit how ‘thinking outside of the box’ can mean a better delivery of health care. The session will be of value to all members of the health care team.
0945-1015
Refreshment Break
1015-1100
Healthcare in the Armed Forces
Michel Duperré, MLT, MWO, Adjum, Senior National Medical Laboratory Technologist, CF H, Svcs Gp HQ, D Med Pol, Department of National Defense, Government of Canada
General Objectives:
At the end of this session participants will be able to:
- I will explain the Canadian Armed Forces Health Services laboratory structure.
- The participants will discover laboratory testing equipment in non-traditional environments.
- I will also discuss the many challenge (HR, consumable etc.) lab technologist are confronted with on deployment.
The session will be valuable to any healthcare professional who has interest in laboratory services in non-traditional environment. This presentation is a brief sample of what the military Health Care Laboratory Services can provide on deployment. You will see how medical laboratory service members react and overcome challenges while on deployment.
1100-1200
EPOCC Lightening Talks
Miranda Brun, Department of Lab Medicine and Pathology, University of Alberta, Edmonton AB
Jake Cosme, University of Toronto, Toronto ON
Jay Kalra, Department of Pathology, Royal University Hospital, Saskatoon SK
Peter Kavsak, Core Lab, Juravinski Hospital and Cancer Centre, Hamilton ON
Curtis Oleschuk, Clinical Biochemistry and Genetics, Diagnostic Service of Manitoba, Winnipeg MB
Jason Robinson, Clinical Biochemistry – Calgary Laboratory Services, Calgary AB
General Objectives:
At the end of this session participants will be able to:
- Succinctly describe 6 current topics in clinical chemistry.
- Outline an algorithm for providing critical feedback on the content and organization of a 5 minute presentation.
- Discuss key features of effective communication strategies.
Show Me the Data: Enable the Transition from Volume to Value Using Your Electronic Health Record
Roche Diagnostics
Monday June 4, 1400-1500
Patrick C. Mathias, M.D., Ph.D.
General Objectives:
At the conclusion of this session, participants will be able to:
- Describe effective laboratory stewardship strategies.
- Identify data that assists in selecting test ordering improvement opportunities.
- Implement EHR interventions to promote laboratory stewardship.
Did you know that implementing simple laboratory practices such as analyzing different characteristics of laboratory orders to identify potential test ordering improvement opportunities and one or more electronic health record (EHR) interventions can help improve your lab’s stewardship efforts? In this workshop, Patrick C. Mathias, M.D., Ph.D., shows you how using data can help your laboratory enable a transition from volume to value.
Managing the Risk of Patient Harm from Erroneous Results
Bio-Rad Laboratories (Canada) Ltd.
Monday June 4, 1400-1500
Danny Gauvreau, Bio-Rad Laboratories
John Yundt-Pacheco, Bio-Rad Laboratories
General Objectives:
At the conclusion of this session, participants will be able to:
- Understand how a QC strategy relates to the risk of producing erroneous results during an out-of-control condition.
- Understand how test method performance, reliability, and clinical utility affect our tolerance for erroneous results.
- Understand how to determine an acceptable probability of patient harm.
- Understand how to compute a predicted probability of patient harm for a test method.
- Understand how to compute a risk management index, comparing predicted probability of patient harm with acceptable probability of patient harm.
This workshop will provide participants with examples of how to evaluate QC strategies in the presence of out-of-control conditions. Once the basic concepts and metrics are covered, they will be used to derive expressions for predicting the rate of producing erroneous results during in-control and out-of-control conditions. An approach for relating erroneous results and patient harm will be covered as will as how to determine acceptable levels of patient harm for a test method. We will end with a discussion of how to compute a risk management index comparing predicted probability of patient harm with acceptable probability of patient harm.
Integrating Procalcitonin into Clinical Diagnosis and Management of Septic Patients to Provide Measurably Better Healthcare
Abbott Laboratories
Monday June 4, 1400-1500
Eric Howard Gluck, M.D.
General Objectives:
At the conclusion of this session, participants will be able to:
- To understand the mechanisms of sepsis and optimal management of septic and potentially septic patients.
- To appreciate the challenges that physicians face when diagnosing sepsis and the importance of integrated clinical care strategies.
- To highlight the value of Procalcitonin-guided treatment pathways for measurable benefits to patients, clinicians, health systems and payors.
Sepsis is a topic of national interest due to its high mortality rate, the time-sensitive nature of providing the appropriate care and the significant financial burden on healthcare systems. Current methods for the diagnosis of sepsis are often non-specific or slow, delaying treatment and/or increasing the possibility of over-treatment. Patient treatment can be enhanced by the use of procalcitonin (PCT), a protein produced and released in response to a bacterial infection. This workshop will review healthcare implications of sepsis, discuss implementation of PCT into clinical care and highlight the measurable benefits of PCT-guided pathwayians, health systems and payors.
Initial Method Validation of the Randox Multistat System in a Routine Clinical Biochemistry Laboratory
ESBE Scientific
Monday June 4, 1600-1700
Dr. Nathalie Lepage, PhD, FCACB, Hôpital Montfort
Renee-Claude Baril, Hôpital Montfort
Pankaj Sinha, Randox Toxicology
General Objectives:
At the conclusion of this session, participants will be able to:
- Discuss a new multiplexing technology with future application to the clinical toxicology setting.
The session will cover the scientific fundamentals of Randox biochipTM multiplex technology and it’s application for use as a urine toxicology screening tool. Evaluation test results and operational performance of the biochip with Randox’s smallest platform called MultiSTAT will be discussed in detail.
High-Sensitivity Cardiac Troponin – A Test That Offers High-Expectations for Laboratories, Clinicians, and Patients
Beckman Coulter Canada
Monday June 4, 1600-1700
Pete Kavsak, Hamilton Health Sciences
Joe Bottos, Beckman Coulter Canada
Pankaj Sinha, Randox Toxicology
General Objectives:
At the conclusion of this session, participants will be able to:
- Current consensus on the definition of high-sensitivity cardiac troponin (hs-cTn) assay, any new criteria.
- Better understand the Impact of hs-cTn on clinical practice: ED, patients outside of ACS diagnosis.
- Better understand pre-analytical and analytical issues lab professions should pay attention to.
High-sensitivity cardiac troponin: what does it mean to your laboratory, your clinicians, and your patients.
How Engineering Design and Biochemistry Come Together to Improve Patient Care; Atellica™ Solution Assays in a New Light
Siemens
Monday June 4, 1600-1700
Frank Vitzhum, Global Assay Development, Siemens Healthineers
General Objectives:
At the conclusion of this session, participants will be able to:
- Learn basic procedural aspects of the development of assay products.
- Understand how certain key features of certain critical components of an assay formulation, in particular acridinium-esters and their conjugates, impact the performance of an assay.
- Learn how engineering features can improve the assay time and the precision of an assay without the need for changing formulations.
The workshop will provide an overview of the development process for assays at Siemens Healthineers. With a focus on immunoassays using the acridinium-ester technology, approaches are discussed on how performance characteristics, in particular assay sensitivity, as well as manufacturability and lot-to-lot consistency can be improved. This will be discussed using examples like the High Sensitivity Troponin I assay. Furthermore, examples from Atellica Solution will be presented to explain benefits of engineering design on time to first result and precision without changing the biochemistry of an assay.
Management of Dysglycemia in Critically Ill Patients – Importance of Glucose Meter Accuracy
Nova Biomedical
Tuesday June 5, 0730-0830
Evan Ntrivalas, MD, PhD, HCLD/CC(ABB), D(ABLMLI), Director of Medical and Scientific Affairs, Nova Biomedical, USA
General Objectives:
At the conclusion of this session, participants will be able to:
- Identify common errors in point of care glucose testing.
- Describe the effect of interferences on POC glucose testing in hospitalized patients.
- Understand the importance of glucose meter accuracy in improving clinical outcomes.
- List the clinical benefits of proper glycemic management in critically ill patients.
Point-of-Care (POC) glucose testing in the hospital is a valuable tool for the management of dysglycemia. This can be undermined by inaccurate POC glucose meter results, which are most often caused by interferences related to patients’ pathophysiologic factors and exogenous substances. The presentation will discuss, using peer-reviewed publications and clinical case studies, the risks posed by interferences in glucose meter results, and how these can potentially affect patient’s safety. Additional factors (such as regulatory issues, user-related errors, and competency assessment) that can have an effect in POC glucose meter performance and potentially influence clinical outcomes will be discussed.
Managing Preanalytic Change in Large Healthcare Systems
BD Canada
Tuesday June 5, 0730-0830
Dr. Anna Fuezery, Alberta Health Services, Calgary AB
Dr. Philippe Mills
General Objectives:
At the conclusion of this session, participants will be able to:
- Describe considerations that go into deciding whether to implement a new blood collection tube for a single versus multiple analytes across a large healthcare system.
- Describe challenges associated with the implementation of a preanalytical change across a large healthcare system.
- Describe change management strategies for the implementation of a preanalytical change across a large healthcare system.
In late 2016 BD Canada released a new blood collection tube called Barricor. The novel, mechanical separation technology of this tube produces a more complete separation of cellular contents from plasma, eliminates gel artifacts, improves sample stability and is only slightly more expensive than BD’s plasma separator tube (PST). Within a span of 6 months in 2017, Alberta Health Services implemented this tube for troponin testing at 13 sites across Edmonton that ranged from a large quaternary care center to a standalone emergency room. In the beginning of 2018, CIUSSS de la Mauricie-et-du-Centre-du-Quebec implemented the tube for all chemistry testing at 9 sites across the region of Trois-Rivieres, with the sites ranging from a tertiary care center to a stand-alone emergency room. This workshop will feature two speakers, each of whom will describe their organization’s approach to the implementation of the tubes. Topics that will be discussed include: 1) reasons behind choosing to implement the Barricor for a single versus multiple analytes; 2) change management pre- and post-implementation, with particular emphasis on the large scale of each implementation; and 3) lessons learned. The workshop will consist of a 5 minute introduction of the speakers, two 25 minute presentations (one presentation per speaker), and a 5 minute question-and-answer period.
Symposium: Hot Topics in Toxicology: The Opioid Crisis and Cannabis Legalization
Tuesday June 5, 0900-1200
General Objectives:
The general objectives for the symposium are:
- Recognize the issues of treating opioid addiction.
- Describe the challenges of laboratory measurement of fentanyl and its analogues.
- Discuss the short and long-term consequences of cannabis medicalization and legalization.
0900-0950
The Opioid Crisis: From Patient Care to Regulation
Marina Reinecke, Director, CPD Medicine Program, University of Manitoba
Learning Objectives:
At the end of this session participants will be able to:
- Discuss the opioid crisis and the resulting human toll.
- Examine the continuum of pain, addiction and everything in between.
- Describe how the opioid crisis is threatening the physician-patient relationship.
- Identify evidence-based treatment for opioid addiction and the laboratory services that support treatment.
- Summarize regulatory efforts to address the opioid crisis in Manitoba.
- Propose what still needs to be done.
The opioid crisis continues to have a profound impact on Canadians. Physicians are challenged to manage pain and opioid addiction effectively, while protecting the public from the harms of diverted medications. This session will explore the human toll of the opioid crisis as well as the strain the modern physician-patient relationship is under. We will review evidence based treatment for opioid addiction and the laboratory services that are essential in supporting our patients on their recovery journeys. We will also take a look at the medical regulatory landscape and the impact increasing regulation of prescribing practices is having on our work and our patients. This session will be of value to: Clinical Chemists, trainees, medical laboratory technologists, pathologists and other healthcare professionals.
0950-1020
Refreshment Break
1020-1110
Laboratory Testing for Opioids
Jessica Boyd, Clinical Biochemist, Calgary Laboratory Services
Learning Objectives:
At the end of this session participants will be able to:
- Discuss the origins of the opioid crisis and its impact on Canadian laboratories.
- Compare available testing methods for opioids.
- Summarize the challenges in testing for fentanyl and its analogues.
The opioid crisis is a public health emergency affecting all areas of health care, including the clinical laboratory. This presentation will summarize the origins of the crisis and the impact on the clinical laboratory, with particular focus on Alberta. Available testing methods for opioids, including LC-MS/MS, and their utility in detection fentanyl and its analogues will also be discussed. This session will be of value to: Clinical Chemists, trainees, medical laboratory technologists, pathologists and other healthcare professionals.
1110-1200
THC: The Great Cannabis Experiment
Marilyn Huestis, Senior Fellow, Lambert Center for the Study of Medicinal Cannabis & Hemp
Learning Objectives:
At the end of this session participants will be able to:
- Describe the endogenous cannabis system.
- Describe the effect of cannabis on lateral control.
- Describe the rapidity with which ∆9-tetrahydrocannabinol leaves the blood after cannabis inhalation.
- Explain the advantages and limitations of oral fluid testing for cannabis.
This session will cover the short and long-term effects of cannabis medicalization and commercialization. The presentation will focus on the effects of cannabis on driving and new data from the world’s most advanced driving simulator, and data from the Drug Recognition Examiner study of 302 cannabis only cases. The session will be of value to Clinical Chemists, Trainees, Pathologists and the general public.
Symposium: Informatics: Opportunities and Challenges
Tuesday June 5, 1330-1630
General Objectives:
The general objectives for the symposium are:
- Identify how informatics can improve information dissemination.
- Discuss collaborative informatics opportunities in Canada.
- Describe privacy and regulatory aspects of laboratory data use and re-use.
1330-1420
Utilization Informatics
Christopher T. Naugler,Professor and Head, Department of Pathology and Laboratory Medicine, University of Calgary
This presentation will describe gaps in current knowledge regarding lab utilization in Canada, particularly with regards to inter-provincial benchmarking. The This presentation will describe gaps in current knowledge regarding lab utilization in Canada, particularly with regards to inter-provincial benchmarking. The Canadian Laboratory Informatics Collaboration will attempt to fill this gap. The session will be of value to: Clinical Chemists, Trainees, and other healthcare professionals.
Learning Objectives:
At the end of this session participants will be able to:
- Identify major recent trends in pathology informatics.
- Identify gaps in current knowledge in pathology informatics.
- Describe the proposed purpose of the Canadian Laboratory Informatics Collaboration.
1420-1510
Health Information Exchange: The Exelleris Story
François Chevallier, VPs Technologies Ltd., LifeLabs, Vancouver BC Canada
Learning Objectives:
At the end of this session participants will be able to:
- Summarize how the Exelleris platform integrates a series of patient data in BC.
- Summarize how the Excelleris platform supports the on-line delivery of health information to physicians and patients.
- Discuss benefits of data aggregation and accessibility through connected healthcare systems.
The presentation demonstrates how Excelleris Technologies is an integral part of the provincial eHealth ecosystems in multiple jurisdictions in Canada, providing comprehensive health information access to healthcare providers and patients. The presentation will also show how the Excelleris platform is used to connect healthcare providers and patients through Health Information Exchange.
Target audience: healthcare professionals
1510-1540
Refreshment Break
1540-1630
Big Data, Big Responsibilities: Privacy, Data Breaches and De-identification
Fida Hindi, Legal Counsel, Information and Privacy Commissioner of Ontario
David Weinkauf, Senior Policy and Technology Advisor, Office of the Information and Privacy Commissioner of Ontario
The bigger the data, the greater the responsibility to protect the privacy of individuals. While big data and the growing use of information technologies pose challenges to some of the key principles of data protection, it is possible to protect privacy so long as appropriate measures are put in place to mitigate the risks.
This session will provide a broad overview of the Office of the Information and Privacy Commissioner’s guidelines on big data, de-dentification, mandatory breach reporting and communicating personal health information by email. We will identify the risks to privacy posed by these new technologies and modes of communication while providing helpful strategies to prevent improper uses of personal health information and help ensure compliance with relevant privacy laws.
Learning Objectives:
At the end of this session participants will be able to:
- List the main privacy concerns raised by big data.
- Discuss the re-identification risks of improperly de-identified data.
- Identify breach reporting requirements under the Personal Health Information Protection Act.
- Identify risks and requirements of communicating personal health information by email.
Symposium: Specialized Topics in Laboratory Medicine
Wednesday June 6, 0900-1200
General Objectives:
The general objectives for the symposium are:
- Describe the presentations and laboratory testing for allergies and other immunological disorders.
- Identify current concepts in porphyrias including diagnosis and classification, laboratory testing and an overview of treatment approaches.
- Identify current approaches to HIV testing.
0900-0950
Immunology & Allergy Testing
Reza Alizadehfar, Training Program Director, Associate Professor of Pediatrics, Division of Allergy & Clinical Immunology, Montréal Children’s Hospital, Montréal General Hospital, McGill University
Learning Objectives:
At the end of this session participants will be able to:
- Discuss diagnosis of an IgE-mediated allergic disorder.
- Be familiar with in vivo investigation of allergic disorders.
- Understand the role and pitfalls of in vitro investigation of allergic diseases.
Selection of allergy diagnostic testing and the interpretation of the results MUST be only directed, guided, and viewed within the context of the patient’s clinical history. This session will be of value to Clinical biochemists and Trainees.
0950-1020
Refreshment Break
1020-1110
Porphyria
Aasne K. Aarsand, Norwegian Porphyria Centre (NAPOS), Laboratory of Clinical Biochemistry, Haukeland University, Bergen Norway
The porphyrias are a group of uncommon, inborn error of metabolism diseases. They are caused by partial deficiency, or in one disease increased activity, in one of the enzymes of heme biosynthesis, causing overproduction of heme pathway intermediates which are excreted in excessive amounts in urine, feces, or both. The porphyrias typically present with acute neurovisceral attacks and/or photosensitivity symptoms, with the clinical consequences depending on the nature of heme precursors that accumulate. The diagnoses are established on laboratory investigations demonstrating the pattern of heme precursor accumulation and excretion specific for each type of porphyria. DNA analysis is rarely necessary for diagnosis of symptomatic cases, but is the method of choice for healthy at-risk elatives. Treatment options are for most porphyrias limited and several of the diseases are associated with a low quality of life and serious long-term complications. This session will provide updated information on clinical characteristics, appropriate diagnostics and treatment options for the porphyrias and will be of value to laboratory physicians, clinical chemists, trainees, and other healthcare professionals.
Learning Objectives:
At the end of this session participants will be able to:
- Identify the main clinical characteristics of the different porphyrias.
- Select the appropriate diagnostic tests for each disorder and provide interpretation of results.
- Identify useful resources for providing advice on treatment and follow-up.
1110-1200
HIV Diagnostics: Evolving Technologies and New Testing Algorithms
Gerasimos J. Zaharatos, Attending Staff, Jewish General Hospital and Assistant Professor, Department of Medicine, Division of Infectious Diseases, Department of Microbiology, McGill University
Learning Objectives:
At the end of this session participants will be able to:
- Employ the laboratory HIV testing algorithm currently recommended in North America.
- Describe how immunoassay-based testing for HIV has evolved with regard to diagnostic sensitivity, specificity and window per.
- Delineate the differences between HIV Western Blot and HIV-1/2 Differentiation Assays.
- Discuss nucleic acid amplification testing methods that can be used to adjudicate indeterminate immunoassay results.
Laboratory HIV testing algorithms continue to evolve with the introduction of new technologies and strong clinical recommendations to begin treatment shortly after diagnosis, irrespective of immunologic or virologic status. This session will provide an overview of current laboratory HIV testing recommendations and detail how immunoassay-based testing for HIV has changed over the last two decades. The advantages of supplemental testing by HIV-1/2 differentiation assays and nucleic acid amplification testing methods will also be discussed. The session will be of value to clinical chemists, medical biochemists, microbiologists, trainees, and other healthcare professionals.